These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
546 related articles for article (PubMed ID: 23813874)
1. Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era. Nagle SJ; Woo K; Schuster SJ; Nasta SD; Stadtmauer E; Mick R; Svoboda J Am J Hematol; 2013 Oct; 88(10):890-4. PubMed ID: 23813874 [TBL] [Abstract][Full Text] [Related]
2. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. Mounier N; Canals C; Gisselbrecht C; Cornelissen J; Foa R; Conde E; Maertens J; Attal M; Rambaldi A; Crawley C; Luan JJ; Brune M; Wittnebel S; Cook G; van Imhoff GW; Pfreundschuh M; Sureda A; Biol Blood Marrow Transplant; 2012 May; 18(5):788-93. PubMed ID: 22005647 [TBL] [Abstract][Full Text] [Related]
3. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study. Redondo AM; Pomares H; Vidal MJ; Pascual MJ; Quereda B; Sancho JM; Polo M; López J; Conde E; Jarque I; Alonso N; Ramírez MJ; Fernández P; Sayas MJ; Requena MJ; Salar A; González JD; González-Barca E; Arranz R; Caballero D; Martín A Br J Haematol; 2014 Mar; 164(5):668-74. PubMed ID: 24274082 [TBL] [Abstract][Full Text] [Related]
4. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission. Papajik T; Raida L; Faber E; Vondrakova J; Prochazka V; Kubova Z; Skoumalova I; Jarosova M; M LK; Paucek B; Myslivecek M; Neoral C; Oral I; Jarkovsky J; Dusek L; Indrak K Neoplasma; 2008; 55(3):215-21. PubMed ID: 18348654 [TBL] [Abstract][Full Text] [Related]
5. Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era. Hunter BD; Herr M; Meacham PJ; Barlaskar F; Evans AG; Burack WR; Liesveld JL; Becker MW; Milner LA; Constine LS; Dhakal S; Barr PM; Friedberg JW; Casulo C Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):145-151. PubMed ID: 27998707 [TBL] [Abstract][Full Text] [Related]
6. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group. Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic results in patients with relapsed diffuse large B cell Non-Hodgkin's lymphoma achieving complete response only after autologous stem cell transplantation. Ferrara F; Viola A; Copia C; Schiavone EM; Celentano M; Pollio F; D'Amico MR; Palmieri S Hematol Oncol; 2006 Jun; 24(2):73-7. PubMed ID: 16550628 [TBL] [Abstract][Full Text] [Related]
8. Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era. Biswas T; Dhakal S; Chen R; Hyrien O; Bernstein S; Friedberg JW; Fisher RI; Liesveld J; Phillips G; Constine LS Int J Radiat Oncol Biol Phys; 2010 May; 77(1):79-85. PubMed ID: 19647953 [TBL] [Abstract][Full Text] [Related]
9. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma]. Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686 [TBL] [Abstract][Full Text] [Related]
10. Role of hematopoietic stem cell transplantation for advanced-stage diffuse large cell B-cell lymphoma-B. Nademanee A; Forman SJ Semin Hematol; 2006 Oct; 43(4):240-50. PubMed ID: 17027658 [TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. Armand P; Welch S; Kim HT; LaCasce AS; Jacobsen ED; Davids MS; Jacobson C; Fisher DC; Brown JR; Coughlin E; Freedman AS; Chen YB Br J Haematol; 2013 Mar; 160(5):608-17. PubMed ID: 23278720 [TBL] [Abstract][Full Text] [Related]
12. Induction chemotherapy followed by up-front autologous stem cell transplantation may have a survival benefit in high-risk diffuse large B-cell lymphoma patients. Shin HJ; Yoon DH; Lee HS; Oh SY; Yang DH; Kang HJ; Chong SY; Park Y; Do Y; Lim SN; Jo JC; Lee WS; Chung JS; Exp Hematol; 2016 Jan; 44(1):3-13. PubMed ID: 26325332 [TBL] [Abstract][Full Text] [Related]
13. Comparison of clinical outcome after autologous stem cell transplantation between patients with peripheral T-cell lymphomas and diffuse large B-cell lymphoma. Sohn BS; Park I; Kim EK; Yoon DH; Lee SS; Kang BW; Jang G; Choi YH; Kim C; Lee DH; Kim S; Huh J; Suh C Bone Marrow Transplant; 2009 Sep; 44(5):287-93. PubMed ID: 19234508 [TBL] [Abstract][Full Text] [Related]
14. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission. Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255 [TBL] [Abstract][Full Text] [Related]
15. Patients with diffuse large B cell lymphoma in partial response or stable disease after first-line R-CHOP: the prognostic value of the absolute lymphocyte count and impact of autologous stem cell transplantation. Hung MH; Yu YB; Huang YC; Liu HT; Hong YC; Hsiao LT; Liu JH; Gau JP; Chiou TJ; Chen PM; Tzeng CH; Liu CY Ann Hematol; 2012 Dec; 91(12):1907-15. PubMed ID: 22885989 [TBL] [Abstract][Full Text] [Related]
16. Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma. Fruchart C; Tilly H; Morschhauser F; Ghesquières H; Bouteloup M; Fermé C; Van Den Neste E; Bordessoule D; Bouabdallah R; Delmer A; Casasnovas RO; Ysebaert L; Ciappuccini R; Briere J; Gisselbrecht C Biol Blood Marrow Transplant; 2014 Dec; 20(12):1905-11. PubMed ID: 25072780 [TBL] [Abstract][Full Text] [Related]
17. Autologous Stem Cell Transplant in Fit Patients With Late Relapsed Diffuse Large B-Cell Lymphoma That Responded to Salvage Chemotherapy. Tun AM; Wang Y; Maliske S; Micallef I; Inwards DJ; Habermann TM; Porrata L; Paludo J; Bisneto JV; Rosenthal A; Kharfan-Dabaja MA; Ansell SM; Nowakowski GS; Farooq U; Johnston PB Transplant Cell Ther; 2024 Oct; 30(10):1001.e1-1001.e12. PubMed ID: 38996973 [TBL] [Abstract][Full Text] [Related]
18. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. Ohmachi K; Niitsu N; Uchida T; Kim SJ; Ando K; Takahashi N; Takahashi N; Uike N; Eom HS; Chae YS; Terauchi T; Tateishi U; Tatsumi M; Kim WS; Tobinai K; Suh C; Ogura M J Clin Oncol; 2013 Jun; 31(17):2103-9. PubMed ID: 23650408 [TBL] [Abstract][Full Text] [Related]
19. Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score. Peters AC; Duan Q; Russell JA; Duggan P; Owen C; Stewart DA Leuk Lymphoma; 2011 Nov; 52(11):2124-9. PubMed ID: 21740097 [TBL] [Abstract][Full Text] [Related]